Loading...

Anthera Pharmaceuticals, Inc.

ANTHPNK
Healthcare
Biotechnology
$0.00
$0.00(0.00%)

Anthera Pharmaceuticals, Inc. (ANTH) Company Profile & Overview

Explore Anthera Pharmaceuticals, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Anthera Pharmaceuticals, Inc. (ANTH) Company Profile & Overview

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

SectorHealthcare
IndustryBiotechnology
CEOPaul F. Truex

Contact Information

410 350 1839
The Pennzoil Building, Houston, TX, 77002

Company Facts

21 Employees
IPO DateMar 1, 2010
CountryUS
Actively Trading

Frequently Asked Questions

;